Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | VHL | P40337 | 1/20 | 0.43 |
| ▸ | ELOC | Q15369 | 1/20 | 0.43 |
| ▸ | ELOB | Q15370 | 1/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9032903 | 0.86 | MEN1 (0.55) | MEN1KMT2AGAAALDH1A1VHL | |
| SCHEMBL8471402 | 0.80 | NOX1 (0.43) | MEN1KMT2AGAAVHLELOC | |
| SCHEMBL6204345 | 0.77 | MEN1 (0.53) | MEN1KMT2AGAAALDH1A1IDO1 | |
| SCHEMBL1816443 | 0.77 | MEN1 (0.53) | MEN1KMT2AGAAALDH1A1RYR2 | |
| SCHEMBL10226479 | 0.77 | GAA (0.53) | MEN1KMT2AGAAALDH1A1RYR2 | |
| SCHEMBL8038619 | 0.77 | MEN1 (0.53) | MEN1KMT2AGAAALDH1A1RYR2 | |
| SCHEMBL30804421 | 0.73 | RYR2 (0.63) | MEN1KMT2AGAAALDH1A1NOX1 | |
| SCHEMBL3054155 | 0.73 | ALDH1A1 (0.49) | MEN1KMT2AGAAALDH1A1RYR2 | |
| SCHEMBL12692912 | 0.73 | ALDH1A1 (0.49) | MEN1KMT2AGAAALDH1A1RYR2 | |
| SCHEMBL3070838 | 0.73 | MEN1 (0.49) | MEN1KMT2AGAAALDH1A1RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023169-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SipA) | UNIVERSITY OF MASSACHUSETTS | 2021-01-28 | — | — | US | disclosed |
| US-10835575-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | UNIVERSITY OF MASSACHUSETTS (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190240286-A1 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) | UNIVERSITY OF MASSACHUSETTS | 2019-08-08 | — | — | US | disclosed |
| US-10201589-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | UNIVERSITY OF MASSACHUSETTS (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170035837-A1 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) | UNIVERSITY OF MASSACHUSETTS (US) | 2017-02-09 | — | — | US | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20140140962-A1 | VIRUSES MODIFIED WITH UNNATURAL MOIETIES AND METHODS OF USE THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140086939-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-03-27 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040191843-A1 | Cell-killing molecules and methods of use thereof | PALO ALTO INSTITUTE OF MOLECULAR MEDICINE | 2004-09-30 | — | — | US | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060405-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20030216758-A1 | Coated surgical patches | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2003-11-20 | — | — | US | disclosed |
| US-20030144570-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2003-07-31 | — | — | US | disclosed |
| EP-1235598-A2 | COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS | Angiotech Pharmaceuticals, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| US-20020055666-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH INTERNATIONAL AG (CH) | 2002-05-09 | — | — | US | disclosed |
| WO-2001036007-A2 | COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023169-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SipA) | TP53, CIP2A, ABCC1 | MEN1 2845/4885KMT2A 3358/4885GAA 1450/4885 |
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | CD44, SELP, EPCAM | MEN1 4597/4885KMT2A 4793/4885GAA 3485/4885 |
| US-10835575-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | TP53, CIP2A, ABCC1 | MEN1 2845/4885KMT2A 3358/4885GAA 1450/4885 |
| US-20190240286-A1 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) | TP53, CIP2A, ABCC1 | MEN1 2845/4885KMT2A 3358/4885GAA 1450/4885 |
| US-20170035837-A1 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) | TP53, CIP2A, ABCC1 | MEN1 2845/4885KMT2A 3358/4885GAA 1450/4885 |
| US-10201589-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | TP53, CIP2A, ABCC1 | MEN1 2845/4885KMT2A 3358/4885GAA 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.